MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 198 filers reported holding MYRIAD GENETICS INC in Q2 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $16,395,111 | -30.7% | 1,022,139 | +0.2% | 0.00% | -40.0% |
Q2 2023 | $23,641,305 | +2.1% | 1,019,901 | +2.3% | 0.01% | 0.0% |
Q1 2023 | $23,164,840 | +58.2% | 997,195 | -1.2% | 0.01% | +66.7% |
Q4 2022 | $14,645,755 | -36.2% | 1,009,356 | -16.2% | 0.00% | -40.0% |
Q3 2022 | $22,969,000 | +2.3% | 1,203,781 | -2.6% | 0.01% | 0.0% |
Q2 2022 | $22,463,000 | -28.3% | 1,236,245 | -0.6% | 0.01% | -16.7% |
Q1 2022 | $31,340,000 | -11.6% | 1,243,663 | -3.2% | 0.01% | 0.0% |
Q4 2021 | $35,461,000 | -14.6% | 1,284,822 | -0.1% | 0.01% | -14.3% |
Q3 2021 | $41,520,000 | +3.0% | 1,285,843 | -2.5% | 0.01% | 0.0% |
Q2 2021 | $40,317,000 | +4.8% | 1,318,425 | +4.3% | 0.01% | 0.0% |
Q1 2021 | $38,474,000 | +13.6% | 1,263,491 | -26.2% | 0.01% | 0.0% |
Q4 2020 | $33,857,000 | +39.5% | 1,712,116 | -8.0% | 0.01% | +40.0% |
Q3 2020 | $24,266,000 | +11.3% | 1,860,855 | -3.3% | 0.01% | 0.0% |
Q2 2020 | $21,812,000 | -19.4% | 1,923,384 | +1.8% | 0.01% | -37.5% |
Q1 2020 | $27,046,000 | -47.2% | 1,890,036 | +0.5% | 0.01% | -27.3% |
Q4 2019 | $51,224,000 | -5.7% | 1,881,132 | -0.8% | 0.01% | -15.4% |
Q3 2019 | $54,307,000 | +8.9% | 1,896,815 | +5.6% | 0.01% | +8.3% |
Q2 2019 | $49,879,000 | -11.2% | 1,795,468 | +6.1% | 0.01% | -14.3% |
Q1 2019 | $56,171,000 | +14.2% | 1,691,878 | -0.0% | 0.01% | 0.0% |
Q4 2018 | $49,189,000 | -35.5% | 1,692,079 | +2.1% | 0.01% | -26.3% |
Q3 2018 | $76,269,000 | +13.3% | 1,658,013 | -8.0% | 0.02% | +11.8% |
Q2 2018 | $67,337,000 | +29.9% | 1,801,882 | +2.7% | 0.02% | +30.8% |
Q1 2018 | $51,827,000 | -8.6% | 1,753,888 | +6.2% | 0.01% | -7.1% |
Q4 2017 | $56,703,000 | +2.2% | 1,650,968 | +7.7% | 0.01% | 0.0% |
Q3 2017 | $55,465,000 | +66.1% | 1,533,034 | +18.6% | 0.01% | +55.6% |
Q2 2017 | $33,400,000 | +76.4% | 1,292,588 | +31.1% | 0.01% | +80.0% |
Q1 2017 | $18,937,000 | +15.2% | 986,312 | +0.0% | 0.01% | 0.0% |
Q4 2016 | $16,439,000 | -21.6% | 986,163 | -3.2% | 0.01% | -28.6% |
Q3 2016 | $20,973,000 | -33.2% | 1,019,141 | -0.6% | 0.01% | -30.0% |
Q2 2016 | $31,379,000 | -19.3% | 1,025,504 | -1.3% | 0.01% | -23.1% |
Q1 2016 | $38,895,000 | -12.2% | 1,039,033 | +1.3% | 0.01% | -13.3% |
Q4 2015 | $44,285,000 | +18.1% | 1,026,064 | +2.6% | 0.02% | +15.4% |
Q3 2015 | $37,487,000 | +113.2% | 1,000,173 | +93.4% | 0.01% | +160.0% |
Q2 2015 | $17,580,000 | +15.9% | 517,214 | +20.7% | 0.01% | 0.0% |
Q1 2015 | $15,168,000 | +5.5% | 428,463 | +1.5% | 0.01% | +25.0% |
Q4 2014 | $14,383,000 | -13.4% | 422,312 | -1.9% | 0.00% | -20.0% |
Q3 2014 | $16,612,000 | +8.4% | 430,686 | +9.4% | 0.01% | 0.0% |
Q2 2014 | $15,330,000 | -3.3% | 393,853 | -15.1% | 0.01% | 0.0% |
Q1 2014 | $15,857,000 | +83.8% | 463,804 | +12.8% | 0.01% | +66.7% |
Q4 2013 | $8,628,000 | -1.3% | 411,231 | +10.6% | 0.00% | 0.0% |
Q3 2013 | $8,740,000 | -9.3% | 371,872 | +3.7% | 0.00% | 0.0% |
Q2 2013 | $9,636,000 | – | 358,577 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |